Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
80 enrolled
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Phase 2/3 Recruiting
120 enrolled
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Phase 2/3 Recruiting
120 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
TroFuse-021
Phase 3 Recruiting
900 enrolled
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Phase 1 Recruiting
265 enrolled
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Phase 3 Recruiting
255 enrolled
DO-01
Phase 3 Recruiting
582 enrolled
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Phase 2 Recruiting
20 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
RAINFOL-04
Phase 3 Recruiting
528 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
GLORIOSA
Phase 3 Recruiting
520 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Phase 1 Recruiting
90 enrolled
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Phase 1 Recruiting
34 enrolled
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Phase 2 Recruiting
96 enrolled
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
Phase 1 Recruiting
207 enrolled
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 Recruiting
495 enrolled
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 Recruiting
880 enrolled
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Phase 1/2 Recruiting
120 enrolled
Autophagy Maintenance (AUTOMAIN)
Phase 2 Recruiting
38 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
54 enrolled
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1/2 Recruiting
150 enrolled
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3 Recruiting
970 enrolled
EndoMAP
Phase 1/2 Recruiting
148 enrolled
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
582 enrolled
DAB
Phase 2 Recruiting
39 enrolled
HS-10502
Phase 1 Recruiting
157 enrolled
DOVE
Phase 2 Recruiting
198 enrolled
SCENIC
Phase NA Recruiting
18 enrolled
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2 Recruiting
100 enrolled
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Phase 2 Recruiting
60 enrolled
OVNI-B
Recruiting
300 enrolled
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Phase 2 Recruiting
220 enrolled
A Study of ZN-c3 in Patients With Ovarian Cancer
Phase 1 Recruiting
140 enrolled
NIRVANA-1
Phase 2 Recruiting
390 enrolled
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
Phase 2 Recruiting
244 enrolled
STROBE
Phase 2 Recruiting
100 enrolled
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 1/2 Recruiting
48 enrolled
PTST_PALBEVA
Phase 1 Recruiting
50 enrolled
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Phase 2 Recruiting
42 enrolled